A Phase II/III randomised, comparative, multicentre Study to Evaluate the Safety and Immunogenicity of Biological E's Live, Attenuated Measles-Rubella Vaccine (MR) in 9-12 month old Healthy Infants. - None

Trial Profile

A Phase II/III randomised, comparative, multicentre Study to Evaluate the Safety and Immunogenicity of Biological E's Live, Attenuated Measles-Rubella Vaccine (MR) in 9-12 month old Healthy Infants. - None

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Measles and rubella virus vaccine (Primary)
  • Indications Measles; Rubella
  • Focus Pharmacodynamics
  • Sponsors Biological E Limited
  • Most Recent Events

    • 06 Feb 2017 Status changed from not yet recruiting to active, no longer recruiting.
    • 02 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top